Search - tctmd.com

Displaying 221 - 240 of 1354

Sort: Relevancy | Date

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

News Daily News

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

October 19, 2022

Anatomic Features Key for Selecting Patients Best Suited to PFO Closure

News Daily News

Anatomic Features Key for Selecting Patients Best Suited to PFO Closure

Yael L. Maxwell

October 14, 2022

AI-ECG Strategy Identifies Patients at Risk for AF

News Daily News

AI-ECG Strategy Identifies Patients at Risk for AF

September 30, 2022

Initiative Lowers Unnecessary Aspirin Use in Warfarin Users

News Daily News

Initiative Lowers Unnecessary Aspirin Use in Warfarin Users

September 26, 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

Anticoagulation for PE: When to Switch to DOACs?

Presentation TCT 2022

Anticoagulation for PE: When to Switch to DOACs?

Presenter: Behnood Bikdeli

September 19, 2022

Presentation TCT 2022

TCT 359: Continued Oral Anticoagulation With Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists in Transcatheter Aortic Valve Implantation

Presenter: Norman Mangner

September 19, 2022

Anticoagulation Strategies in High-Risk PE: Are DOACs Enough? When Do We Switch?

Presentation TCT 2022

Anticoagulation Strategies in High-Risk PE: Are DOACs Enough? When Do We Switch?

Presenter: Teresa Carman

September 19, 2022

TCT 766: Exclusion of left atrial appendage with thrombus in a patient with contraindication of oral anticoagulation

Presentation TCT 2022

TCT 766: Exclusion of left atrial appendage with thrombus in a patient with contraindication of oral anticoagulation

Presenter: Claudio Cigalini

September 18, 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

September 18, 2022

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

News Conference News TCT 2022

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

September 17, 2022

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presentation TCT 2022

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Marc Bonaca

September 17, 2022

2bIIIA Inhibitors and Bleeding Risk When Complications Develop: Risks vs. Benefits of Anticoagulation Agents

Presentation TCT 2022

2bIIIA Inhibitors and Bleeding Risk When Complications Develop: Risks vs. Benefits of Anticoagulation Agents

Presenter: Craig Beavers

September 16, 2022

VITAL Rhythm Data May Flip the Script on AF Screening in Women

News Daily News

VITAL Rhythm Data May Flip the Script on AF Screening in Women

September 08, 2022

Late Bleeding Not Rare, Ups Mortality After TAVI in All-Asian Cohort: OCEAN-TAVI

News Daily News

Late Bleeding Not Rare, Ups Mortality After TAVI in All-Asian Cohort: OCEAN-TAVI

Yael L. Maxwell

September 08, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Watchman FLX Gets DAPT Option Added to Label

News Daily News

Watchman FLX Gets DAPT Option Added to Label

September 06, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.